Latent-Y: The Autonomous AI Agent for Drug Design at Scale

Contributed by: Business Wire

Logo

Tags

Software

Research

Professional Services

Pharmaceutical

Data Management

Venture Capital

Technology

Artificial Intelligence

Health Technology

Science

Biotechnology

Health

Other Science

Latent-Y

More Like This

PR Newswire associated0

Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery

PR Newswire associated0

DeepL unveils autonomous AI agent for businesses

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure

Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine

Overview of Research (Graphic: Business Wire)

A research paper on AI-driven drug discovery by SAKURA internet and COGNANO was accepted by NeurIPS 2024, a prestigious AI conference

PR Newswire associated0

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic

LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes